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therapy induced HPV lesions in the HIV positive
patients?–Multiple case reportsKishore Shetty a,*, Janet Leigh ba University of Texas Health Sciences Center, Medically Complex Patient Clinic, Department of Restorative Dentistry,
6516 MD Anderson Boulevard, Suite 475, Houston, TX 77030, United States
b LSU Health Sciences Center, New Orleans, United StatesReceived 25 October 2005; accepted 26 October 2005Summary The increases incidence of oral human papillomavirus (HPV) in patients infected
with the human immunodeficiency virus (HIV) is of concern and is the focus of numerous current
research studies. Recent studies have shown an increased risk of oral warts in HIV-infected indi-
viduals despite treatment with highly active antiretroviral therapy (HAART). There seems to be
a predilection for the labial mucosa as a site specific for occurrence for oral warts. This reports
presents a series of case reports documenting the same observation.c 2005 Elsevier Ltd. All rights reserved.
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dCase # 1
A 36-year-old African-American male presented to the den-
tal clinic for evaluation of multiple lesions on the lower
lip. The patient medical history was significant for human
immunodeficiency virus (HIV) infection and manic depres-
sion. The patient was highly active antiretroviral drug ther-
apy for the past 18 months. Intraoral exam examination
revealed multiple papillary lesions on the lower labial
mucosa ranging from 0.6 to 1.0 cm in diameter (Fig. 1).
There were no other oral lesions, tumors or masses noted
intraorally. The patients had a CD4 count of 509 with a
viral load of 8000. The patient was presently on Nevirapine741-9409/$ - see front matter c 2005 Elsevier Ltd. All rights reserved
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E-mail address: shettyk@yahoo.com (K. Shetty).(Viramune; Boehringer Ingelheim Corporation, Connecticut,
USA), lopinavir/ritonavir (Kaletra; Abbott Laboratories,
Illinois, USA) and abacavir (Ziagen; Glaxosmithkline, Munich,
Germany). The patient was also on sulfamethoxazole-
trimethoprim q M-W-F (Bactrim DS; Hoffmann-LaRoche,
New Jersey, USA). Cephalexin 500 mg QID for seven days
(Keflex; Novopharm, Toronto, Canada) and chlorhexidine
gluconate 0.12% oral rinse (Peridex; Zila Pharmaceuticals,
Arizona, USA). The patient agreed to undergo an excisional
biopsy of the lesions and the histologic signout diagnosis
was consistent papilloma from each site biopsied.
Case # 2
A 45-year-old African diagnosed with HIV and hepatitis B
in 2003 presented to the dental clinic for evaluation and.
Figure 2 Patient # 2 with multiple papillary raised lesions on
the lower right labial mucosa.
Figure 3 Patient # 3 with multiple raised papillary to nodular
lesions on the upper labial mucosa.
Figure 4 Patient # 4 with multiply papillary lesions ranging
from 0.2 to 0.8 cm in diameter on maxillary labial and alveolar
mucosa.
Figure 1 Patient #1 with multiple papillary lesions on the
lower labial mucosa.
164 K. Shetty, J. Leightreatment for multiple oral lesions on the lips. The patient
was on HAART since diagnosis. The intraoral exam revealed
multiple papillary raised lesions on the lower right labial
mucosa (Fig. 2).
The CD4 count range since his diagnosis was 202–468/ul
with an undetectable viral load. Anti-retroviral medications
included: lamivudine (Epivir; GlaxoSmithKline, North
Carolina, USA), nevirapine (Viramune; Boehringer Ingelheim
Corporation, Connecticut, USA) and lopinavir/ritonavir
(Kaletra; Abbott Laboratories, Illinois, USA). The histologic
examination of the oral lesions was signed out as benign
papillomas. The patient subsequently underwent laser abla-
tion therapy for removal of these lesions.
Case # 3
A 27-year-old African was referred by his general practi-
tioner for evaluation of asymptomatic oral lesions on his
lips. The intraoral exam revealed multiple raised papillary
to nodular lesions on the upper labial mucosa ranging from
0.8 cm to 1.6 cm in diameter (Fig. 3). The patient wasrecently diagnosed with HIV infection and had been on
antiretrovirals for the past three months. The patient had
a CD4 count of 175/ul with an undetectable viral load.
The patient was on highly active antiretrovirals—nevirapine
(Viramune, Boehringer Ingelheim Pharmaceuticals, Ridge-
field, CT; 800.243.0127), ritonavir (Kaletra; Abbott Labora-
tories, Abbott Park, IL; 800.255.5162), and abacavir
(Ziagen; Glaxosmithkline); lamivudine/zidovudine (Combi-
vir; GlaxoSmithKline, North Carolina, USA) and lopinavir/
ritonavir (Kaletra; Abbott Laboratories, Illinois, USA). The
patient underwent incisional biopsy for the oral lesions
under local anesthesia. The histologic examination revealed
a benign papillary lesion consistent with a diagnosis of
papilloma.
Case # 4
A 22-year-old African-American male presented to the clinic
for evaluation of multiple oral lesions. The patient was re-
cently diagnosed with HIV (four months) and was started
on the highly active antiretroviral drug therapy. He first no-
ticed the lesions on his lips three weeks after starting his
antiretroviral medications. Intraoral exam examination
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0.8 cm in diameter disseminated intraorally on the labial
and buccal mucosa (Fig. 4). There were no other oral
lesions, tumors or masses noted intraorally. Review of
systems was unremarkable with no otalgia, dysphagia,
odynophagia, hoarseness or coughing. The patient’s extra
oral exam revealed a normocephalic facial symmetry with
no signs or symptoms of acute infection, swelling or tender-
ness. The patient did not have any other significant medical
history. His CD4 count was 220 and the viral load
was 20,500. The patient was presently on a regimen of
nevirapine (Viramune; Boehringer Ingelkeim Corporation,
Connecticut, USA), Ritonavir (Kaletra; Abbott Laboratories,
IL, USA), ABACAVIR (Ziagen; Glaxosmithkline, Munich,
Germany) and efavirenz (Sustiva; Bristol Myers Squibb,
Chicago, USA). There was no history of tobacco, alcohol or
illicit drug use. The patient agreed to undergo an incisional
biopsy of the lesions on two different sites in the maxillary
and mandibular region. The histologic examination revealed
a benign papillary lesion consistent with a diagnosis of
papilloma from each site biopsied. The patient was referred
to the oral and maxillofacial surgery clinic for laser ablation
of the papillary lesions.Discussion
Papillomaviruses are a large family of DNA viruses capable
of infecting a variety of epithelial surfaces, including both
mucosal and cutaneous epithelium. Over 100 distinct geno-
types of HPV have been identified (based on the genetic se-
quence of the L1, E6 and E7 ORFs), and at least 30 of these
have been detected in the oral cavity. The gross appearance
of oral warts varies greatly and often reflects the specific
HPV genotype causing the lesion.1,2 For instance, HPV geno-
types 6 and 11, the most common causes of genital warts,
tend to cause soft cauliflower-like lesions (condyloma accu-
minatum) in the oral cavity. These infections can be chronic
and cause recurrent respiratory papillomatosis (RRP). HPV
genotypes 1, 2, and 7, which are associated with cutaneous
warts, are often the cause of firm oral common warts (ver-
ruca vulgaris). HPV genotypes 13 and 32, which have been
described exclusively in the oral cavity, are found in oral
focal epithelial hyperplasia (FEH), a rare dysplastic lesion
characterized by multiple small, flat papules that affects
Eskimos, American Indians and HIV positive individuals.
Unusual manifestations of HPV in the HIV positive patient
frequently occur,1 and clinical appearance alone is not
sufficient for assessing the HPV genotype present in an oral
lesion.
Highly active antiretroviral treatment (HAART) is associ-
ated with peripheral reconstitution of cellular immunity and
great advances in terms of lower incidence of opportunistic
infections, fewer hospital admissions, and fewer deaths due
to AIDS.
Systemic immune reconstitution with highly active anti-
retroviral therapy (HAART) has led to decreases in systemic
and oral infections, including regression in HPV-induced cer-
vical lesions.3,4 Since the advent of HAART, the incidences
of oral opportunistic infections have significantly de-
creased.5 In stark contrast, the authors reported an increase
in incidence of oral papillomas (warts) since the advent ofHAART.6 This was followed by a report in Lancet which
clearly demonstrated not only a rise in the incidence of oral
warts in the 1990s but also a significant association between
the rise in warts and HAART.7 Increased incidence of oral
warts concurrent with a drop in plasma HIV viral load was
subsequently reported in the Atlanta HIV cohort by King
et al.8
The majority of cases of HPV infection are asymptom-
atic, and the development of HPV pathology is a rare event
that occurs only after prolonged infection. Unlike oral hairy
leukoplakia, which occurs almost exclusively on the tongue,
and oropharyngeal candidiasis, which occurs on either the
tongue or buccal mucosa, papillomas due to HPV infection
can occur on virtually all oral mucosal surfaces namely the
buccal mucosa, the tongue, the soft palate, and the gingiva.
The histopathology of oral warts almost invariably demon-
strates poorly differentiated, large, vacuolated koilocytic
cells, but the gross appearance varies greatly. Often, the
clinical appearance of lesions is reflective of the specific
HPV genotype causing the lesion. For instance, HPV geno-
types 6 and 11, the most common causes of genital warts,
tend to cause soft, sessile, cauliflower-like lesions (condy-
loma accuminatum) in the oral cavity. HPV genotypes 1,
2, and 7, which are associated with cutaneous warts, cause
firm, sessile, oral common warts (verruca vulgaris). HPV
genotypes 13 and 32, which have been described exclusively
in the oral cavity, are the cause of oral focal epithelial
hyperplasia, a dysplastic lesion characterized by multiple
small, flat papules generally found on the lower lip. While
there is some degree of HPV genotype-specific clinical pre-
sentation, unusual manifestations of oral HPV disease in the
HIV positive patient frequently occur.8
The present observation on the preponderance of oral
warts on the labial mucosa has significant implications on
management. The treatment of oral warts in the HIV patient
is difficult due to both the wide distribution of lesions
throughout the labial mucosa and the high recurrence rate.
Although these lesions are generally painless, they can be-
come traumatized and interfere with eating and talking
and can also look unsightly when present externally on the
lips. Treatments include both medical and surgical modali-
ties, depending on the site of the wart, the characteristics
of the wart, and the number of lesions.9Summary
The current clinical observation of oral warts on labial mu-
cosa due to HPV in the HIV+ individual merits further consid-
eration. There seems to be a predilection for the labial
mucosa as a site specific for occurrence for oral warts in
the HIV positive patients on highly active antiretroviral
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